KR101656237B1 - 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 - Google Patents

표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 Download PDF

Info

Publication number
KR101656237B1
KR101656237B1 KR1020157022593A KR20157022593A KR101656237B1 KR 101656237 B1 KR101656237 B1 KR 101656237B1 KR 1020157022593 A KR1020157022593 A KR 1020157022593A KR 20157022593 A KR20157022593 A KR 20157022593A KR 101656237 B1 KR101656237 B1 KR 101656237B1
Authority
KR
South Korea
Prior art keywords
dna
lys
leu
guide rna
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157022593A
Other languages
English (en)
Korean (ko)
Other versions
KR20150101477A (ko
Inventor
김진수
조승우
김소정
Original Assignee
주식회사 툴젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50544909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101656237(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사 툴젠 filed Critical 주식회사 툴젠
Publication of KR20150101477A publication Critical patent/KR20150101477A/ko
Application granted granted Critical
Publication of KR101656237B1 publication Critical patent/KR101656237B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157022593A 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 Active KR101656237B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261717324P 2012-10-23 2012-10-23
US61/717,324 2012-10-23
US201361803599P 2013-03-20 2013-03-20
US61/803,599 2013-03-20
US201361837481P 2013-06-20 2013-06-20
US61/837,481 2013-06-20
PCT/KR2013/009488 WO2014065596A1 (en) 2012-10-23 2013-10-23 Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013868A Division KR102182847B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20150101477A KR20150101477A (ko) 2015-09-03
KR101656237B1 true KR101656237B1 (ko) 2016-09-12

Family

ID=50544909

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020157013868A Active KR102182847B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020157022594A Active KR101706085B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020187006398A Active KR102052286B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020157022593A Active KR101656237B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020157022592A Active KR101656236B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020157013868A Active KR102182847B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020157022594A Active KR101706085B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR1020187006398A Active KR102052286B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157022592A Active KR101656236B1 (ko) 2012-10-23 2013-10-23 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도

Country Status (16)

Country Link
US (14) US20150284727A1 (OSRAM)
EP (12) EP3372679A1 (OSRAM)
JP (10) JP6517143B2 (OSRAM)
KR (5) KR102182847B1 (OSRAM)
CN (9) CN110592089B (OSRAM)
AU (6) AU2013335451C1 (OSRAM)
BR (1) BR112015008708A2 (OSRAM)
CA (2) CA3233048A1 (OSRAM)
DE (2) DE202013012597U1 (OSRAM)
DK (2) DK2912175T3 (OSRAM)
ES (4) ES2926021T3 (OSRAM)
HK (1) HK1257302A1 (OSRAM)
PL (2) PL4357457T3 (OSRAM)
PT (1) PT2912175T (OSRAM)
SG (3) SG10201809566SA (OSRAM)
WO (1) WO2014065596A1 (OSRAM)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054427A (ko) * 2016-11-14 2018-05-24 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
WO2018117377A1 (ko) * 2016-12-22 2018-06-28 주식회사 툴젠 Fad2 유전자 조작된 올레인산 강화 식물체 및 이의 제조 방법
KR20190038449A (ko) * 2017-09-29 2019-04-08 서울대학교산학협력단 Klotho 유전자 넉아웃 질환모델 동물 및 이의 용도
US11352666B2 (en) 2014-11-14 2022-06-07 Institute For Basic Science Method for detecting off-target sites of programmable nucleases in a genome
WO2023282688A1 (ko) 2021-07-09 2023-01-12 주식회사 툴젠 산화스트레스 저항성을 갖는 중간엽 줄기세포, 이의 제조방법 및 용도
WO2023008933A1 (ko) 2021-07-29 2023-02-02 주식회사 툴젠 혈액 적합성을 갖는 중간엽 줄기세포, 이의 제조방법 및 용도
WO2023167575A1 (ko) 2022-03-04 2023-09-07 주식회사 툴젠 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포 및 이의 제조방법
WO2023219434A1 (ko) 2022-05-13 2023-11-16 주식회사 툴젠 혈액 적합성을 갖는 혈관 내 이식용 세포, 이의 제조방법 및 용도
US12509697B2 (en) 2023-11-29 2025-12-30 Toolgen Incorporated Oleic acid-enriched plant body having genetically modified FAD2 and production method thereof

Families Citing this family (436)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129373A2 (en) 2011-03-23 2012-09-27 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US10501791B2 (en) 2011-10-14 2019-12-10 President And Fellows Of Harvard College Sequencing by structure assembly
ES2991004T3 (es) 2011-12-22 2024-12-02 Harvard College Métodos para la detección de analitos
WO2014163886A1 (en) 2013-03-12 2014-10-09 President And Fellows Of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
KR101904508B1 (ko) 2012-04-25 2018-10-04 리제너론 파마슈티칼스 인코포레이티드 큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
KR20230065381A (ko) * 2012-07-25 2023-05-11 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
WO2014065596A1 (en) 2012-10-23 2014-05-01 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
AU2013355214B2 (en) * 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
EP4299741A3 (en) * 2012-12-12 2024-02-28 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN119752887A (zh) * 2012-12-12 2025-04-04 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CA2894668A1 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP4481048A3 (en) 2012-12-17 2025-02-26 President and Fellows of Harvard College Rna-guided human genome engineering
WO2014150624A1 (en) 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140273235A1 (en) * 2013-03-15 2014-09-18 Regents Of The University Of Minnesota ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2014165825A2 (en) * 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
WO2014172470A2 (en) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
RS62263B1 (sr) 2013-04-16 2021-09-30 Regeneron Pharma Ciljana modifikacija genoma pacova
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
US20160122774A1 (en) * 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
MY177814A (en) * 2013-06-04 2020-09-23 Harvard College Rna-guided transcriptional regulation
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
CN105531372A (zh) 2013-06-14 2016-04-27 塞尔克蒂斯股份有限公司 植物中非转基因基因组编辑方法
EP3011031B1 (en) 2013-06-17 2020-09-30 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
DK3011029T3 (da) 2013-06-17 2020-03-16 Broad Inst Inc Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering
WO2014204727A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
KR20160056869A (ko) 2013-06-17 2016-05-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
IL243475B2 (en) * 2013-07-09 2023-11-01 Harvard College Multiplex rna-guided genome engineering
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
KR102243597B1 (ko) 2013-08-16 2021-04-26 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
US20160208272A1 (en) 2013-08-22 2016-07-21 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015040402A1 (en) 2013-09-18 2015-03-26 Kymab Limited Methods. cells & organisms
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
PT3066201T (pt) 2013-11-07 2018-06-04 Massachusetts Inst Technology Métodos e composições relacionadas com crispr com arng reguladores
US10787684B2 (en) * 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
ES2700596T3 (es) 2013-12-11 2019-02-18 Regeneron Pharma Métodos y composiciones para la modificación dirigida de un genoma
RU2725520C2 (ru) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CA2932479A1 (en) 2013-12-12 2015-06-18 The Rockefeller University Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
KR20160097327A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
KR20250068794A (ko) 2013-12-12 2025-05-16 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
CN106103705A (zh) 2013-12-12 2016-11-09 布罗德研究所有限公司 核苷酸重复障碍中crispr‑cas系统的组合物和使用方法
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
CA2938456C (en) 2014-02-11 2022-06-21 The Regents Of The University Of Colorado, A Body Corporate Crispr enabled multiplexed genome engineering
RU2016136977A (ru) 2014-02-18 2018-03-20 Дьюк Юниверсити Композиции для инактивации репликации вируса и способы их получения и применения
EP3971283A1 (en) 2014-02-27 2022-03-23 Monsanto Technology LLC Compositions and methods for site directed genomic modification
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
SG11201609211VA (en) * 2014-03-05 2016-12-29 Nat Univ Corp Univ Kobe Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3116997B1 (en) 2014-03-10 2019-05-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
EP3126495A1 (en) 2014-04-02 2017-02-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
EP3152221A4 (en) * 2014-05-20 2018-01-24 Regents of the University of Minnesota Method for editing a genetic sequence
WO2015183025A1 (ko) * 2014-05-28 2015-12-03 주식회사 툴젠 표적 특이적 뉴클레아제를 이용한 표적 dna의 민감한 검출 방법
WO2015188065A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
JP6688231B2 (ja) 2014-06-06 2020-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的遺伝子座を修飾するための方法及び組成物
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
DK3354732T3 (da) 2014-06-23 2020-04-06 Regeneron Pharma Nukleasemedieret dna-samling
WO2015200555A2 (en) * 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
US20150376587A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
AU2015288157A1 (en) 2014-07-11 2017-01-19 E. I. Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
US10179932B2 (en) 2014-07-11 2019-01-15 President And Fellows Of Harvard College Methods for high-throughput labelling and detection of biological features in situ using microscopy
ES3047792T3 (en) * 2014-07-14 2025-12-04 Univ California Crispr/cas transcriptional modulation
CN112941065A (zh) * 2014-07-21 2021-06-11 亿明达股份有限公司 使用crispr-cas系统的多核苷酸富集
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN106536721B (zh) * 2014-08-06 2020-12-04 车医科学大学校产学协力团 核酸酶介导的编辑编码hla的基因所产生的免疫相容性细胞
WO2016021973A1 (ko) * 2014-08-06 2016-02-11 주식회사 툴젠 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
US11071289B2 (en) 2014-08-14 2021-07-27 Biocytogen Boston Corp DNA knock-in system
NZ728437A (en) 2014-08-27 2018-02-23 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
EP3188763B1 (en) 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification
EP3628739B1 (en) 2014-09-12 2024-05-01 Corteva Agriscience LLC Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
CN104212836A (zh) * 2014-09-18 2014-12-17 东华大学 一种在哺乳动物细胞系中敲除mir-505的方法
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
JP6612340B2 (ja) 2014-10-15 2019-11-27 セージ サイエンス， インコーポレイテッド 核酸の自動化された加工処理および電気泳動による試料調製のための装置、方法およびシステム
KR20170070136A (ko) 2014-10-15 2017-06-21 리제너론 파마슈티칼스 인코포레이티드 만능성 세포를 생성하거나 유지하는 방법 및 조성물
GB201418965D0 (OSRAM) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
CN107109362A (zh) 2014-10-31 2017-08-29 麻省理工学院 递送生物分子至免疫细胞
CN107406838A (zh) * 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
WO2016073955A2 (en) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
AU2015342749B2 (en) * 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
WO2016076672A1 (ko) * 2014-11-14 2016-05-19 기초과학연구원 유전체에서 유전자 가위의 비표적 위치를 검출하는 방법
IL301900A (en) 2014-11-21 2023-06-01 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
EP4400584A3 (en) 2014-12-03 2024-10-16 Agilent Technologies, Inc. Guide rna with chemical modifications
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016100272A1 (en) 2014-12-16 2016-06-23 Danisco Us Inc Fungal genome modification systems and methods of use
JP2017538427A (ja) 2014-12-18 2017-12-28 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Ｃｒｉｓｐｒ系組成物及び使用方法
WO2016100857A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
EP3653048B9 (en) 2014-12-19 2023-10-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
WO2016115179A1 (en) * 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
EP3279321A4 (en) 2015-03-16 2018-10-31 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Method of applying non-genetic substance to perform site-directed reform of plant genome
EP3271461A1 (en) * 2015-03-20 2018-01-24 Danmarks Tekniske Universitet Crispr/cas9 based engineering of actinomycetal genomes
EP3274453B1 (en) * 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
CN107567499A (zh) 2015-03-27 2018-01-09 纳幕尔杜邦公司 大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
WO2016172727A1 (en) 2015-04-24 2016-10-27 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
JP2018515139A (ja) 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
KR101785847B1 (ko) 2015-05-12 2017-10-17 연세대학교 산학협력단 선형 이중가닥 ＤＮＡ를 활용한 ＣＲＩＳＰＲ／Ｃａｓ９ 시스템을 이용한 표적 유전체 교정
EP3095870A1 (en) 2015-05-19 2016-11-23 Kws Saat Se Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
CN108026536A (zh) 2015-05-29 2018-05-11 北卡罗来纳州立大学 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
CN108368502B (zh) 2015-06-03 2022-03-18 内布拉斯加大学董事委员会 使用单链dna的dna编辑
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
EP4299754A3 (en) 2015-06-15 2024-03-20 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
KR102840885B1 (ko) 2015-06-18 2025-07-30 더 브로드 인스티튜트, 인코퍼레이티드 표적외 효과를 감소시키는 crispr 효소 돌연변이
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
EP4545544A3 (en) 2015-06-29 2025-10-08 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
WO2017008063A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
CN107849562B (zh) * 2015-07-28 2021-10-26 丹尼斯科美国公司 基因组编辑系统及使用方法
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
US9580727B1 (en) 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
WO2017027910A1 (en) 2015-08-14 2017-02-23 The University Of Sydney Connexin 45 inhibition for therapy
EA201890565A1 (ru) 2015-08-25 2019-04-30 Дьюк Юниверсити Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2017053312A1 (en) * 2015-09-21 2017-03-30 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
CA3001108A1 (en) * 2015-10-06 2017-04-13 Institute For Basic Science Method for producing whole plants from protoplasts
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US20180282763A1 (en) * 2015-10-20 2018-10-04 Pioneer Hi-Bred International, Inc. Restoring function to a non-functional gene product via guided cas systems and methods of use
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
DK3350327T3 (en) 2015-10-23 2019-01-21 Caribou Biosciences Inc CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
GB2559526B (en) 2015-11-03 2021-02-17 Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
KR101885901B1 (ko) * 2015-11-13 2018-08-07 기초과학연구원 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물
JP7054678B2 (ja) * 2015-11-20 2022-04-14 ワシントン・ユニバーシティ ゲノムｄｎａ断片の標的化された精製のための調製用電気泳動方法
CN106811479B (zh) * 2015-11-30 2019-10-25 中国农业科学院作物科学研究所 利用CRISPR/Cas9系统定点修饰ALS基因获得抗除草剂水稻的系统及其应用
WO2017095944A1 (en) 2015-11-30 2017-06-08 Flagship Pioneering, Inc. Methods and compositions relating to chondrisomes from blood products
WO2017095967A2 (en) 2015-11-30 2017-06-08 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
NZ756843A (en) 2015-12-04 2021-07-30 Caribou Biosciences Inc Engineered nucleic-acid targeting nucleic acids
CN106845151B (zh) * 2015-12-07 2019-03-26 中国农业大学 CRISPR-Cas9系统sgRNA作用靶点的筛选方法及装置
WO2017099494A1 (ko) * 2015-12-08 2017-06-15 기초과학연구원 Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
CN108463229B (zh) 2016-01-11 2023-10-17 斯坦福大学托管董事会 嵌合蛋白和免疫治疗方法
CN109312335B (zh) 2016-01-11 2023-10-24 斯坦福大学托管董事会 嵌合蛋白和调节基因表达的方法
EP3402327A1 (en) * 2016-01-15 2018-11-21 The Jackson Laboratory Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
EP4653048A2 (en) 2016-01-15 2025-11-26 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
WO2017173054A1 (en) * 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US12410416B2 (en) 2016-04-19 2025-09-09 The Broad Institute, Inc. CRISPR enzymes and systems with modified pam specificity
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
EP4613756A3 (en) 2016-04-25 2025-11-12 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
CN107326046A (zh) * 2016-04-28 2017-11-07 上海邦耀生物科技有限公司 一种提高外源基因同源重组效率的方法
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
CN117431234A (zh) * 2016-05-27 2024-01-23 阿迪根有限公司 用于基因组编辑分子的细胞内递送的肽和纳米颗粒
DK3272867T3 (da) 2016-06-02 2019-12-02 Sigma Aldrich Co Llc Anvendelse af programmerbare dna-bindingsproteiner til forbedring af målrettet genommodifikation
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109312386B (zh) * 2016-06-15 2022-10-25 株式会社图尔金 使用中靶靶标和脱靶靶标的多重靶标系统筛选靶特异性核酸酶的方法及其用途
EP3472321A2 (en) * 2016-06-17 2019-04-24 Genesis Technologies Limited Crispr-cas system, materials and methods
WO2017219027A1 (en) * 2016-06-17 2017-12-21 The Broad Institute Inc. Type vi crispr orthologs and systems
ES2981548T3 (es) * 2016-06-20 2024-10-09 Keygene Nv Método para la alteración dirigida del ADN en células vegetales
ES2915562T3 (es) 2016-06-24 2022-06-23 Univ Colorado Regents Métodos para generar bibliotecas combinatorias con código de barras
EP3481431A4 (en) * 2016-07-05 2020-01-01 The Johns Hopkins University CRISPR / CAS9 COMPOSITIONS AND METHODS FOR TREATING CANCER
JP2019520069A (ja) 2016-07-13 2019-07-18 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 藻類宿主細胞用のｃｒｉｓｐｒ−ｃａｓシステム
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
JP7004651B2 (ja) * 2016-07-19 2022-02-04 株式会社バイオダイナミクス研究所 長鎖一本鎖ｄｎａを調製する方法
JP6875500B2 (ja) 2016-07-28 2021-05-26 インスティテュート フォー ベーシック サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ Ｃａｓ９タンパク質およびガイドＲＮＡを含む眼疾患治療用薬学組成物
CN109803530A (zh) 2016-07-29 2019-05-24 瑞泽恩制药公司 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
EP3494220A1 (en) 2016-08-02 2019-06-12 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
KR101710026B1 (ko) 2016-08-10 2017-02-27 주식회사 무진메디 Cas9 단백질 및 가이드 RNA의 혼성체를 함유하는 나노 리포좀 전달체 조성물
KR101856345B1 (ko) * 2016-08-24 2018-06-20 경상대학교산학협력단 CRISPR/Cas9 시스템을 이용하여 APOBEC3H 및 APOBEC3CH 이중-넉아웃 고양이를 제조하는 방법
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
US20190225974A1 (en) * 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
EA201990860A1 (ru) 2016-09-30 2019-10-31 Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
KR102606680B1 (ko) 2016-10-07 2023-11-27 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. Ｓ. 피오게네스 ｃａｓ９ 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
KR101997116B1 (ko) 2016-10-14 2019-07-05 연세대학교 산학협력단 Kras 유전자에 상보적인 가이드 rna 및 이의 용도
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
AU2017355507B2 (en) 2016-11-04 2023-09-21 Flagship Pioneering Innovations V. Inc. Novel plant cells, plants, and seeds
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
US11136567B2 (en) 2016-11-22 2021-10-05 Integrated Dna Technologies, Inc. CRISPR/CPF1 systems and methods
WO2018111947A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing enhancement
KR101748575B1 (ko) * 2016-12-16 2017-06-20 주식회사 엠젠플러스 Ins 유전자 녹아웃 당뇨병 또는 당뇨병 합병증 동물모델 및 이의 제조방법
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
JP2020504612A (ja) * 2016-12-23 2020-02-13 インスティテュート フォー ベーシック サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ 動物胚の塩基編集用組成物および塩基編集方法
JP6994730B2 (ja) * 2016-12-26 2022-02-04 独立行政法人酒類総合研究所 ゲノム編集タンパク質の直接導入による糸状菌ゲノム編集方法
US11859219B1 (en) 2016-12-30 2024-01-02 Flagship Pioneering Innovations V, Inc. Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
KR102515727B1 (ko) * 2017-01-11 2023-03-30 주식회사 툴젠 중첩된 가이드핵산을 이용한 표적 핵산에 특정 핵산 서열을 삽입하기 위한 조성물 및 방법
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
WO2018140899A1 (en) 2017-01-28 2018-08-02 Inari Agriculture, Inc. Novel plant cells, plants, and seeds
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
KR20180102025A (ko) * 2017-03-06 2018-09-14 기초과학연구원 C2c1 엔도뉴클레아제를 포함하는 유전체 교정용 조성물 및 이를 이용한 유전체 교정 방법
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
CA3055306A1 (en) 2017-04-07 2018-10-11 Sage Science, Inc. Systems and methods for detection of genetic structural variation using integrated electrophoretic dna purification
EP3592854A1 (en) 2017-04-13 2020-01-15 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
CN116555353A (zh) 2017-04-20 2023-08-08 E开创生物技术股份有限公司 产生基因修改的动物的方法
WO2018201086A1 (en) 2017-04-28 2018-11-01 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
AU2018263195B2 (en) * 2017-05-05 2022-04-07 Suzhou Qi Biodesign Biotechnology Company Limited Methods for isolating cells without the use of transgenic marker sequences
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
IL271073B2 (en) 2017-06-05 2025-10-01 Regeneron Pharma B4GALT1 Variants and Their Uses
MX2019014640A (es) 2017-06-09 2020-10-05 Editas Medicine Inc Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
KR20200038236A (ko) 2017-06-13 2020-04-10 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 큐론을 포함하는 조성물 및 그의 용도
EP3638317A4 (en) 2017-06-15 2021-03-17 The Regents of The University of California TARGETED NONVIRAL DNA INSERTIONS
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN112501254B (zh) * 2017-07-14 2024-07-19 上海吐露港生物科技有限公司 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
EP3585160A2 (en) 2017-07-31 2020-01-01 Regeneron Pharmaceuticals, Inc. Crispr reporter non-human animals and uses thereof
CA3067872A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
CA3065579A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
EP3663310A4 (en) 2017-08-04 2021-08-11 Peking University TALE RVD SPECIFICALLY RECOGNIZING A DNA BASE MODIFIED BY METHYLATION AND CORRESPONDING APPLICATION
WO2019028686A1 (zh) 2017-08-08 2019-02-14 北京大学 基因敲除方法
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019051419A1 (en) * 2017-09-08 2019-03-14 University Of North Texas Health Science Center Engineered cas9 variants
TW201920661A (zh) 2017-09-18 2019-06-01 大陸商博雅輯因（北京）生物科技有限公司 一種基因編輯t細胞及其用途
EP3690047A4 (en) * 2017-09-28 2021-11-03 Toolgen Incorporated ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION
US11572574B2 (en) 2017-09-28 2023-02-07 Toolgen Incorporated Artificial genome manipulation for gene expression regulation
BR112020003609A2 (pt) 2017-09-29 2020-09-01 Regeneron Pharmaceuticals, Inc. sistema e método para formar uma emulsão
CN111405912B (zh) 2017-09-29 2025-02-14 因特利亚治疗公司 用于基因组编辑的多核苷酸、组合物及方法
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
CN109722414A (zh) 2017-10-27 2019-05-07 博雅辑因（北京）生物科技有限公司 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
KR102770787B1 (ko) 2017-10-27 2025-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
WO2019089804A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Casy compositions and methods of use
CN108192956B (zh) * 2017-11-17 2021-06-01 东南大学 一种基于Cas9核酸酶的DNA检测分析方法及其应用
WO2019103442A2 (ko) 2017-11-21 2019-05-31 한국생명공학연구원 CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN111566121A (zh) 2018-01-12 2020-08-21 巴斯夫欧洲公司 小麦7a染色体上决定每穗小穗数QTL的基因
US12391941B2 (en) 2018-01-23 2025-08-19 Institute For Basic Science Extended single guide RNA and use thereof
US11926835B1 (en) 2018-01-29 2024-03-12 Inari Agriculture Technology, Inc. Methods for efficient tomato genome editing
WO2019156475A1 (ko) * 2018-02-06 2019-08-15 주식회사 진씨커 돌연변이 세포 유리 유전자 분리 키트 및 이를 이용한 돌연변이 세포 유리 유전자 분리 방법
KR102086689B1 (ko) 2018-02-06 2020-03-09 주식회사 진씨커 돌연변이 세포 유리 유전자 분리 키트 및 이를 이용한 돌연변이 세포 유리 유전자 분리 방법
CA3091267A1 (en) 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
JP7706888B2 (ja) 2018-03-14 2025-07-14 エディタス・メディシン、インコーポレイテッド 異常ヘモグロビン症の治療のためのシステム及び方法
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
WO2019204766A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
CN112020560B (zh) * 2018-04-25 2024-02-23 中国农业大学 一种RNA编辑的CRISPR/Cas效应蛋白及系统
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US11866719B1 (en) 2018-06-04 2024-01-09 Inari Agriculture Technology, Inc. Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
KR102035654B1 (ko) * 2018-07-23 2019-10-24 대한민국 항균 펩타이드를 생산하는 돌연변이 곤충 세포주 또는 이의 제조방법
US11459551B1 (en) 2018-08-31 2022-10-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2020055187A1 (ko) * 2018-09-12 2020-03-19 기초과학연구원 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
WO2020072254A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
KR102081962B1 (ko) * 2018-10-11 2020-02-26 충남대학교 산학협력단 아밀로이드 전구 단백질 유전자를 절단하기 위한 조성물
EP3867376A1 (en) 2018-10-18 2021-08-25 Intellia Therapeutics, Inc. Nucleic acid constructs and methods of use
EP3867378A1 (en) 2018-10-18 2021-08-25 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiencey
MX2021004277A (es) 2018-10-18 2021-09-08 Intellia Therapeutics Inc Composiciones y metodos para expresar el factor ix.
WO2020082042A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for transgene expression from an albumin locus
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
CN111757889B (zh) * 2018-10-29 2021-05-25 中国农业大学 新型CRISPR/Cas12f酶和系统
EP3874048A1 (en) * 2018-11-01 2021-09-08 Keygene N.V. Dual guide rna for crispr/cas genome editing in plants cells
EP3650557B1 (en) * 2018-11-07 2021-10-20 Justus-Liebig-Universität Gießen Method for determination of restriction efficiency of endonucleases mediating double-strand breaks in dna target sequences
US12365923B2 (en) 2018-11-16 2025-07-22 Osaka University Method for producing genome-edited cell
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP7553100B2 (ja) * 2018-12-12 2024-09-18 国立大学法人九州大学 ゲノム編集された細胞の製造方法
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
AU2019398351A1 (en) 2018-12-14 2021-06-03 Pioneer Hi-Bred International, Inc. Novel CRISPR-Cas systems for genome editing
IL301193A (en) 2018-12-20 2023-05-01 Regeneron Pharma Nuclease-mediated repeat expansion
GB2596660B (en) * 2019-01-07 2023-09-13 Crisp Hr Therapeutics Inc A non-toxic Cas9 enzyme and application thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN109868275A (zh) * 2019-03-12 2019-06-11 中国农业大学 CRISPR/Cas9介导的羊FGF5基因敲除和定点整合MTNR1A基因的方法
CN113631700B (zh) 2019-03-18 2025-07-18 瑞泽恩制药公司 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
US11781131B2 (en) 2019-03-18 2023-10-10 Regeneron Pharmaceuticals, Inc. CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
SG11202108451VA (en) 2019-04-03 2021-09-29 Regeneron Pharma Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
KR102487901B1 (ko) 2019-04-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 표적화된 변형의 표적화 벡터로의 무흔적 도입을 위한 방법
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020221291A1 (zh) 2019-04-30 2020-11-05 博雅辑因（北京）生物科技有限公司 一种血红蛋白病治疗有效性预测方法
US11692197B2 (en) 2019-05-06 2023-07-04 Inari Agriculture Technology, Inc. Delivery of biological molecules to plant cells
CN111304180B (zh) * 2019-06-04 2023-05-26 山东舜丰生物科技有限公司 一种新的dna核酸切割酶及其应用
CN113874510A (zh) 2019-06-04 2021-12-31 瑞泽恩制药公司 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
US11845957B2 (en) 2019-06-14 2023-12-19 Regeneron Pharmaceuticals, Inc. Models of tauopathy
US11041172B2 (en) 2019-06-25 2021-06-22 Inari Agriculture, Inc. Homology dependent repair genome editing
CN115244176A (zh) * 2019-08-19 2022-10-25 钟明宏 向导rna-cas蛋白复合物的缀合物
CA3150230A1 (en) 2019-09-04 2021-03-11 Pengfei YUAN METHOD FOR EVALUATING GENE EDITING THERAPY BASED ON OFF-TARGET EVALUATION
AU2020346056A1 (en) 2019-09-13 2022-03-31 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using CRISPR/Cas systems delivered by lipid nanoparticles
CA3147643A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
WO2021061707A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
EP4038190A1 (en) 2019-10-03 2022-08-10 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3158555A1 (en) 2019-10-23 2021-04-29 Pairwise Plants Services, Inc. Compositions and methods for rna-templated editing in plants
CA3160186A1 (en) * 2019-11-05 2021-05-14 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
US20230001019A1 (en) 2019-11-08 2023-01-05 Regeneron Pharmaceuticals, Inc. Crispr and aav strategies for x-linked juvenile retinoschisis therapy
JP7448120B2 (ja) * 2019-11-14 2024-03-12 国立研究開発法人農業・食品産業技術総合研究機構 プラズマを用いてゲノム編集酵素を植物細胞内に導入する方法
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021108442A2 (en) * 2019-11-27 2021-06-03 The Regents Of The University Of California Modulators of cas9 polypeptide activity and methods of use thereof
EP4086340A1 (en) 2019-12-30 2022-11-09 Edigene Biotechnology Inc. Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
WO2021136415A1 (zh) 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
US20230053781A1 (en) 2020-01-14 2023-02-23 Toolgen Incorporated Pharmaceutical composition for preventing or treating alzheimer's and use thereof
WO2021145700A1 (ko) * 2020-01-14 2021-07-22 주식회사 툴젠 저산소 환경 하에서 높은 적응력을 가지는 세포 및 이의 용도
WO2021163515A1 (en) * 2020-02-12 2021-08-19 Temple University - Of The Commonwealth System Of Higher Education Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
KR20210109384A (ko) 2020-02-27 2021-09-06 주식회사 엘지화학 원형질체를 활용한 식물 유전자 교정 효율 증대 방법
EP4114946A1 (en) 2020-03-04 2023-01-11 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
US12057197B2 (en) 2020-04-03 2024-08-06 Creyon Bio, Inc. Oligonucleotide-based machine learning
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CN111690720B (zh) * 2020-06-16 2021-06-15 山东舜丰生物科技有限公司 利用修饰的单链核酸进行靶核酸检测的方法
US20220049303A1 (en) 2020-08-17 2022-02-17 Readcoor, Llc Methods and systems for spatial mapping of genetic variants
KR102638799B1 (ko) * 2020-10-08 2024-02-22 주식회사 진코어 CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도
EP4256052A1 (en) 2020-12-02 2023-10-11 Decibel Therapeutics, Inc. Crispr sam biosensor cell lines and methods of use thereof
KR102878872B1 (ko) * 2020-12-09 2025-10-31 재단법인 아산사회복지재단 온-타겟 활성이 유지되고 오프-타겟 활성이 감소된 가이드 rna 및 이의 용도
CA3206361A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
MX2023007801A (es) 2020-12-30 2023-08-21 Intellia Therapeutics Inc Células t diseñadas.
KR102285906B1 (ko) * 2021-02-18 2021-08-04 주식회사 엔에이피 수생태계 교란어종 관리를 위한 큰입배스 불임 유도용 조성물
WO2022182801A1 (en) 2021-02-25 2022-09-01 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CA3218511A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
KR102616916B1 (ko) * 2021-05-11 2023-12-21 주식회사 애이마 발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
US20230052243A1 (en) 2021-06-02 2023-02-16 Lyell Immunopharma, Inc. Nr4a-deficient cells expressing c-jun and uses thereof
KR102618072B1 (ko) 2021-06-15 2023-12-28 대한민국 작물의 개화조절 관련 유전자 교정용 가이드 rna 및 이의 용도
CA3223311A1 (en) 2021-06-18 2022-12-22 Andrea BARGHETTI Compositions and methods for targeting, editing or modifying human genes
EP4367242A2 (en) 2021-07-07 2024-05-15 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
CN113584134B (zh) * 2021-09-06 2024-01-30 青岛金斯达生物技术有限公司 一种基于CRISPR-Cas9的等温核酸检测系统及其方法和应用
KR20240055811A (ko) 2021-09-10 2024-04-29 애질런트 테크놀로지스, 인크. 프라임 편집을 위한 화학적 변형을 갖는 가이드 rna
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
EP4405463A1 (en) 2021-10-14 2024-07-31 Lonza Sales AG Modified producer cells for extracellular vesicle production
US20240415980A1 (en) 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CA3237300A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
IL312971A (en) 2021-12-08 2024-07-01 Regeneron Pharma Mutant myocilin disease model and uses thereof
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
KR20240133725A (ko) 2021-12-23 2024-09-04 유니버시티 오브 매사추세츠 취약 x 관련 장애의 치료용 치료제
AU2022424002A1 (en) 2021-12-29 2024-06-13 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
US20250032642A1 (en) 2022-02-02 2025-01-30 Regeneron Pharmaceuticals, Inc. Crispr-mediated transgene insertion in neonatal cells
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CN114410609B (zh) * 2022-03-29 2022-07-12 舜丰生物科技(海南)有限公司 一种活性提高的Cas蛋白以及应用
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023205844A1 (en) * 2022-04-26 2023-11-02 Peter Maccallum Cancer Institute Nucleic acids and uses thereof
CN117004604A (zh) * 2022-04-28 2023-11-07 南京北恒生物科技有限公司 一种ciita基因被敲除的工程化免疫细胞及其用途
JP2025514304A (ja) 2022-04-29 2025-05-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
CA3253951A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. NR4A3 Targeted Polynucleotides and Their Uses
EP4526884A2 (en) 2022-05-20 2025-03-26 Artisan Development Labs, Inc. Systems and methods for assessing risk of genome editing events
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
CA3253436A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc IMMUNE RESPONSE COMPOSITIONS AND METHODS
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
EP4532767A2 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating cytokines
KR20250019772A (ko) 2022-05-25 2025-02-11 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
AU2023276715A1 (en) 2022-05-25 2025-01-09 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
CN119421951A (zh) 2022-05-31 2025-02-11 瑞泽恩制药公司 用于c9orf72重复序列扩增疾病的crispr干扰疗法
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
JP2025524469A (ja) 2022-06-24 2025-07-30 チューン セラピューティクス インコーポレイテッド 標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
EP4299739A1 (en) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2024005863A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299733A1 (en) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2024005864A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
CN119562964A (zh) 2022-08-05 2025-03-04 瑞泽恩制药公司 tdp-43的抗聚集变体
CN115386597B (zh) * 2022-09-19 2025-04-25 国家纳米科学中心 一种提高基因载体转染效率和/或转染精度的转染辅助试剂及其应用
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
CA3265590A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. MODIFIED ANTIBODY-RESISTANT RECEPTORS TO IMPROVE CELL-BASED THERAPIES
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
CN120359023A (zh) 2022-11-10 2025-07-22 赛欧生物医药股份有限公司 包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
CN120936364A (zh) 2023-01-27 2025-11-11 瑞泽恩制药公司 修饰的弹状病毒糖蛋白及其用途
WO2024211287A1 (en) 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
WO2024218295A1 (en) 2023-04-21 2024-10-24 Vib Vzw Allelic combinations in crops for yield increase
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2024259309A1 (en) 2023-06-15 2024-12-19 Regeneron Pharmaceuticals, Inc. Gene therapy for hearing disorders
WO2025006963A1 (en) 2023-06-30 2025-01-02 Regeneron Pharmaceuticals, Inc. Methods and compositions for increasing homology-directed repair
TW202519551A (zh) 2023-07-28 2025-05-16 美商雷傑納榮製藥公司 用於治療酸性神經髓磷脂酶缺乏症之抗ＴｆＲ：酸性神經髓磷脂酶
TW202513801A (zh) 2023-07-28 2025-04-01 美商雷傑納榮製藥公司 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
WO2025029654A2 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2025038164A1 (en) * 2023-08-15 2025-02-20 University Of Massachusetts Nick resection in cancer
WO2025049524A1 (en) 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Cxcr4 antibody-resistant modified receptors
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
WO2025056732A1 (en) 2023-09-13 2025-03-20 Medizinische Universität Graz Method for providing antigen-reactive lymphocytes
EP4554371A1 (en) 2023-10-03 2025-05-21 Inari Agriculture Technology, Inc. Viral delivery of grna to the scion
WO2025137439A2 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Engineered t cells
WO2025168705A1 (en) 2024-02-08 2025-08-14 Vib Vzw Means and methods for the production of saponins with endosomal escape-enhancing properties
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025188676A1 (en) * 2024-03-04 2025-09-12 The Board Of Trustees Of The Leland Stanford Junior University Genetic engineering of cells for secretion of therapeutic antibodies
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025224107A1 (en) 2024-04-22 2025-10-30 Basecamp Research Ltd Method and compositions for detecting off-target editing
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025240947A1 (en) 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder
WO2025259669A1 (en) 2024-06-10 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for characterizing modified oligonucleotides

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0262516A2 (en) * 1986-09-29 1988-04-06 Miles Inc. Genetic transformation of lactic acid bacteria
US5350689A (en) * 1987-05-20 1994-09-27 Ciba-Geigy Corporation Zea mays plants and transgenic Zea mays plants regenerated from protoplasts or protoplast-derived cells
IL90161A0 (en) 1988-05-13 1989-12-15 Phillips Petroleum Co Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
US5767367A (en) * 1990-06-23 1998-06-16 Hoechst Aktiengesellschaft Zea mays (L.) with capability of long term, highly efficient plant regeneration including fertile transgenic maize plants having a heterologous gene, and their preparation
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JPH1080274A (ja) 1996-09-06 1998-03-31 Hirofumi Hamada 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター
FR2753204B1 (fr) 1996-09-11 1998-12-04 Transgene Sa Procede de preparation d'adn plasmidique
GB9816138D0 (en) * 1998-07-24 1998-09-23 Ciba Geigy Ag Organic compounds
WO2000055335A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
US6759064B2 (en) 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
WO2002067996A2 (de) 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Beta-endorphin / crf - gentherapie zur lokalen schmerzbekämpfung
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
CA2457059A1 (en) * 2001-08-10 2003-02-20 Ahram Biosystems Inc. System for detecting protease
AU2011203213A1 (en) 2002-08-28 2011-08-04 Chromocell Corporation Selection and Isolation of Living Cells Using mRNA-Binding Probes
JP2005006578A (ja) * 2003-06-20 2005-01-13 Nippon Genetech Co Ltd イン・ビトロ転写反応を利用した機能性ｒｎａ分子の製造方法
SI1667678T1 (sl) 2003-10-03 2009-12-31 Veijlen N V Sestavek za ĺ˝ivalsko hrano
US8685946B2 (en) 2003-11-26 2014-04-01 Universiy of Massachusetts Sequence-specific inhibition of small RNA function
US20050220796A1 (en) 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
WO2005123962A2 (en) * 2004-06-14 2005-12-29 The University Of Texas At Austin Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
US20070048741A1 (en) 2005-08-24 2007-03-01 Getts Robert C Methods and kits for sense RNA synthesis
JP2009506025A (ja) 2005-08-26 2009-02-12 国立大学法人京都大学 抗ウイルス剤及びウイルス複製阻害剤
WO2007142258A1 (ja) * 2006-06-06 2007-12-13 Plant Genome Center Co., Ltd. アントシアニン合成制御遺伝子、およびその利用
NZ579002A (en) 2007-03-02 2012-03-30 Danisco Cultures with improved phage resistance
SI2205749T1 (sl) * 2007-09-27 2016-09-30 Dow Agrosciences, Llc Konstruirani proteini s cinkovim prstom, usmerjeni v 5-enolpiruvil-šikimat-3-fosfat-sintazne gene
EP2188384B1 (en) 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
WO2009137263A2 (en) 2008-04-18 2009-11-12 New Jersey Institute Of Technology Ultra-miniaturized thz communication device and system
WO2010001189A1 (en) 2008-07-03 2010-01-07 Cellectis The crystal structure of i-dmoi in complex with its dna target, improved chimeric meganucleases and uses thereof
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2184292A1 (en) 2008-11-10 2010-05-12 Ulrich Kunzendorf Anti-Apoptotic Fusion Proteins
US8388824B2 (en) 2008-11-26 2013-03-05 Enthone Inc. Method and composition for electrodeposition of copper in microelectronics with dipyridyl-based levelers
KR20100080068A (ko) * 2008-12-31 2010-07-08 주식회사 툴젠 신규한 징크 핑거 뉴클레아제 및 이의 용도
JP5303713B2 (ja) * 2009-02-13 2013-10-02 国立大学法人名古屋大学 冠水応答関連遺伝子及びその利用
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
US8846350B2 (en) * 2009-10-26 2014-09-30 Albert Einstein College Of Medicine Of Yeshiva University MicroRNA affinity assay and uses thereof
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CN107805278A (zh) 2010-04-13 2018-03-16 西格马-奥尔德里奇有限责任公司 产生内源标记的蛋白的方法
EP2569425B1 (en) * 2010-05-10 2016-07-06 The Regents of The University of California Endoribonuclease compositions and methods of use thereof
EP2571512B1 (en) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
WO2012012738A1 (en) 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
JP5721209B2 (ja) * 2010-09-22 2015-05-20 国立研究開発法人農業・食品産業技術総合研究機構 根こぶ病抵抗性アブラナ科植物の作出方法
CN102358902B (zh) * 2011-04-02 2013-01-02 西南大学 家蚕丝素重链基因突变序列及突变的方法和应用
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
SG11201405103SA (en) * 2012-02-24 2014-09-26 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
WO2013141680A1 (en) * 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP2852540B1 (en) 2012-05-23 2016-07-06 Carrier Corporation Climate controlled cargo container
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CN104540382A (zh) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
KR20230065381A (ko) * 2012-07-25 2023-05-11 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
KR20220164090A (ko) * 2012-08-29 2022-12-12 상가모 테라퓨틱스, 인코포레이티드 유전적 병태를 치료하기 위한 방법 및 조성물
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (uk) * 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
WO2014065596A1 (en) 2012-10-23 2014-05-01 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
AU2013355214B2 (en) 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP4299741A3 (en) 2012-12-12 2024-02-28 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2931898B1 (en) * 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US8889559B2 (en) 2012-12-12 2014-11-18 Micron Technology, Inc. Methods of forming a pattern on a substrate
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CN119752887A (zh) 2012-12-12 2025-04-04 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP4481048A3 (en) 2012-12-17 2025-02-26 President and Fellows of Harvard College Rna-guided human genome engineering
FI3491915T3 (fi) * 2012-12-27 2023-08-29 Keygene Nv Menetelmä kohdistetun translokaation indusointiin kasvissa
CN103233028B (zh) * 2013-01-25 2015-05-13 南京徇齐生物技术有限公司 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列
EP2922393B2 (en) * 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
WO2014150624A1 (en) * 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140273235A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2014190181A1 (en) * 2013-05-22 2014-11-27 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
WO2014194190A1 (en) * 2013-05-30 2014-12-04 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
MY177814A (en) 2013-06-04 2020-09-23 Harvard College Rna-guided transcriptional regulation
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
DK3011029T3 (da) 2013-06-17 2020-03-16 Broad Inst Inc Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering
KR20160056869A (ko) 2013-06-17 2016-05-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
ES2767318T3 (es) 2013-06-17 2020-06-17 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
CN105492611A (zh) * 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
EP3011031B1 (en) 2013-06-17 2020-09-30 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
CN103343120B (zh) * 2013-07-04 2015-03-04 中国科学院遗传与发育生物学研究所 一种小麦基因组定点改造方法
US20160208272A1 (en) 2013-08-22 2016-07-21 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
EP3188763B1 (en) * 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jinek et al., Science Vol.337(6096), pp.816-821 (2012. 8. 17.)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352666B2 (en) 2014-11-14 2022-06-07 Institute For Basic Science Method for detecting off-target sites of programmable nucleases in a genome
KR102621539B1 (ko) * 2016-11-14 2024-01-09 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
WO2018088694A3 (ko) * 2016-11-14 2018-08-09 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
US12331086B2 (en) 2016-11-14 2025-06-17 Toolgen Incorporated Artificially engineered SC function control system
KR20180054427A (ko) * 2016-11-14 2018-05-24 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
KR102437228B1 (ko) * 2016-11-14 2022-08-30 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
KR20220122592A (ko) * 2016-11-14 2022-09-02 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
WO2018117377A1 (ko) * 2016-12-22 2018-06-28 주식회사 툴젠 Fad2 유전자 조작된 올레인산 강화 식물체 및 이의 제조 방법
US12286635B2 (en) 2016-12-22 2025-04-29 Toolgen Incorporated Oleic acid-enriched plant body having genetically modified FAD2 and production method thereof
KR102207352B1 (ko) * 2017-09-29 2021-01-26 서울대학교산학협력단 Klotho 유전자 넉아웃 질환모델 동물 및 이의 용도
KR20190038449A (ko) * 2017-09-29 2019-04-08 서울대학교산학협력단 Klotho 유전자 넉아웃 질환모델 동물 및 이의 용도
WO2023282688A1 (ko) 2021-07-09 2023-01-12 주식회사 툴젠 산화스트레스 저항성을 갖는 중간엽 줄기세포, 이의 제조방법 및 용도
WO2023008933A1 (ko) 2021-07-29 2023-02-02 주식회사 툴젠 혈액 적합성을 갖는 중간엽 줄기세포, 이의 제조방법 및 용도
WO2023167575A1 (ko) 2022-03-04 2023-09-07 주식회사 툴젠 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포 및 이의 제조방법
WO2023219434A1 (ko) 2022-05-13 2023-11-16 주식회사 툴젠 혈액 적합성을 갖는 혈관 내 이식용 세포, 이의 제조방법 및 용도
US12509697B2 (en) 2023-11-29 2025-12-30 Toolgen Incorporated Oleic acid-enriched plant body having genetically modified FAD2 and production method thereof

Also Published As

Publication number Publication date
US20150284727A1 (en) 2015-10-08
PL4357457T3 (pl) 2025-03-10
HK1212732A1 (zh) 2016-06-17
CN116064533A (zh) 2023-05-05
US12473559B2 (en) 2025-11-18
EP4549567A2 (en) 2025-05-07
EP4342987A2 (en) 2024-03-27
AU2022204902A1 (en) 2022-08-18
US20250171788A1 (en) 2025-05-29
BR112015008708A2 (pt) 2017-09-26
US20230374525A1 (en) 2023-11-23
CN110643600A (zh) 2020-01-03
JP7571226B2 (ja) 2024-10-22
KR20150101477A (ko) 2015-09-03
EP2912175B1 (en) 2018-08-22
US20240052356A1 (en) 2024-02-15
AU2025203547A1 (en) 2025-06-05
ES3005455T3 (en) 2025-03-14
JP6517143B2 (ja) 2019-05-22
KR20150101476A (ko) 2015-09-03
HK1223125A1 (zh) 2017-07-21
ES2690386T3 (es) 2018-11-20
HK1257301A1 (en) 2019-10-18
US20240240192A9 (en) 2024-07-18
EP2912175A4 (en) 2015-12-09
CA2888190C (en) 2024-04-30
KR102182847B1 (ko) 2020-11-27
US20210047648A1 (en) 2021-02-18
US20250066798A1 (en) 2025-02-27
US20250146002A1 (en) 2025-05-08
CN104968784A (zh) 2015-10-07
AU2013335451A1 (en) 2015-05-07
CN110669758A (zh) 2020-01-10
KR102052286B1 (ko) 2019-12-06
ES2926021T3 (es) 2022-10-21
CN110592089B (zh) 2022-11-01
CA3233048A1 (en) 2014-05-01
EP4397759A2 (en) 2024-07-10
EP4556564A3 (en) 2025-09-03
EP2912175A1 (en) 2015-09-02
ES2886448T3 (es) 2021-12-20
US20250327084A1 (en) 2025-10-23
EP4549567A3 (en) 2025-09-03
JP2022095663A (ja) 2022-06-28
EP4397759A3 (en) 2024-10-09
CN104968784B (zh) 2019-11-05
JP2023166401A (ja) 2023-11-21
EP4180526A2 (en) 2023-05-17
US20210047647A1 (en) 2021-02-18
EP3372679A1 (en) 2018-09-12
US20150322457A1 (en) 2015-11-12
EP4357457A2 (en) 2024-04-24
US20230374524A1 (en) 2023-11-23
CN105441440B (zh) 2020-12-15
EP4567111A2 (en) 2025-06-11
AU2022204902B2 (en) 2025-03-13
KR20180029092A (ko) 2018-03-19
CN110669746B (zh) 2024-04-16
SG10201809564YA (en) 2018-11-29
EP4397760A2 (en) 2024-07-10
AU2013335451B2 (en) 2016-09-15
CN105441440A (zh) 2016-03-30
KR101656236B1 (ko) 2016-09-12
CN116064532A (zh) 2023-05-05
JP2020078303A (ja) 2020-05-28
SG11201503059XA (en) 2015-06-29
US20250122509A1 (en) 2025-04-17
HK1257302A1 (en) 2019-10-18
KR20150101446A (ko) 2015-09-03
SG10201809566SA (en) 2018-11-29
CN110066775B (zh) 2024-03-19
JP7618091B2 (ja) 2025-01-20
WO2014065596A1 (en) 2014-05-01
DE202013012597U1 (de) 2017-11-21
AU2020201485A1 (en) 2020-03-19
JP2018019698A (ja) 2018-02-08
EP3346003B1 (en) 2021-06-09
AU2017254854A1 (en) 2017-11-16
JP2023166400A (ja) 2023-11-21
US10851380B2 (en) 2020-12-01
EP4357457B1 (en) 2024-10-16
KR20150101478A (ko) 2015-09-03
US20240026367A1 (en) 2024-01-25
CN110592089A (zh) 2019-12-20
EP3346003A1 (en) 2018-07-11
JP2016027807A (ja) 2016-02-25
EP4556564A2 (en) 2025-05-21
EP3733847B1 (en) 2022-06-01
JP2024178169A (ja) 2024-12-24
EP4357457A3 (en) 2024-07-17
PL2912175T3 (pl) 2019-03-29
PT2912175T (pt) 2018-11-05
AU2015218519A1 (en) 2015-09-17
EP4180526A3 (en) 2023-06-14
JP2024099674A (ja) 2024-07-25
CA2888190A1 (en) 2014-05-01
EP4397760A3 (en) 2024-10-09
JP2025072369A (ja) 2025-05-09
DK4357457T3 (da) 2025-01-13
CN110066775A (zh) 2019-07-30
US20150344912A1 (en) 2015-12-03
JP2016500003A (ja) 2016-01-07
EP4342987A3 (en) 2024-06-26
DK2912175T3 (en) 2018-10-22
DE202013012610U1 (de) 2017-11-24
CN110669746A (zh) 2020-01-10
AU2013335451C1 (en) 2024-07-04
AU2017254854B2 (en) 2019-12-05
EP3733847A1 (en) 2020-11-04
EP4567111A3 (en) 2025-10-15
KR101706085B1 (ko) 2017-02-14

Similar Documents

Publication Publication Date Title
KR101656237B1 (ko) 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR102389278B1 (ko) 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
HK40020296A (en) System for cleaving a target dna and use thereof
HK40020375B (zh) 用於切割靶dna的组合物及其用途
HK40020314A (en) Composition for cleaving a target dna and use thereof
HK40020375A (en) Composition for cleaving a target dna and use thereof
HK40012112A (en) Composition for cleaving a target dna and use thereof
HK40018765A (en) Composition for cleaving a target dna and use thereof
HK40018765B (en) Composition for cleaving a target dna and use thereof
HK40012112B (zh) 用於切割靶dna的组合物及其用途
HK40040357A (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
HK40040357B (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20190813

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10